Investors love dividend stocks, especially high-yield varieties, because they offer a significant income stream and have substantial total return potential.
It makes a lot of sense to seek dividend-paying stocks for your portfolio. That income, after all, can be reinvested into more shares of stock, and healthy dividend payers tend to increase their payou
Shares of a little-known biotechnology stock called Metsera (MTSR 60.80%) popped on Monday, Sept. 22, after Pfizer (PFE 0.04%) announced it would be acquiring it for a steep premium.
Pfizer is fattening its drug portfolio by betting that more people will want to slim down. The New York drugmaker announced Monday that it's acquiring Metsera, and its portfolio of four medications fo
Evan Seigerman, BMO Capital Markets head of healthcare research, joins 'The Exchange' to discuss Pfizer's obesity drug prospects, competitors and much more.

Pfizer Inc. (PFE) M&A Call Transcript

01:33pm, Monday, 22'nd Sep 2025
Pfizer Inc. (NYSE:PFE ) M&A Call September 22, 2025 8:00 AM EDT Company Participants Francesca DeMartino - Chief Investor Relations Officer Chris Boshoff - Chief Scientific Officer and President of Re

Why Pfizer Stock Just Popped

01:28pm, Monday, 22'nd Sep 2025
Pfizer (PFE 0.56%), the one-time COVID vaccine hero turned Ozempic craze zero, is marching higher Monday after announcing it will try to recover from its danuglipron setback by buying another drug com
SAN DIEGO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, PLLP, has launched an investigation into whether the board members of Metsera, Inc. (NASDAQ: MTSR) breached th
Pfizer Inc (NYSE:PFE) stock is up 2.6% to trade at $24.65 at last check, after the pharma giant revealed it will buy weight-loss drug company Metsera (MTSR) in a deal valued up to $7.3 billion.
Pfizer Inc (NYSE:PFE, ETR:PFE) on Monday announced that it will acquire Metsera, Inc (NASDAQ: MTSR), a weight-loss drug developer, in a deal valued at up to $7.3 billion, or $47.50 per share in c
Metsera (MTSR) shares skyrocketed 60% in premarket trading after Pfizer (PFE) agreed to purchase the biopharma firm for up to $7.3 billion to jump into the lucrative weight-loss drug segment. Shares o
Pfizer Inc. PFE on Monday agreed to acquire Metsera, Inc. MTSR to accelerate the next generation of medicines for obesity and cardiometabolic diseases.
Pfizer said it would acquire weight loss biotech Metsera in a deal valued at up to $7.3 billion, including future payments, as it scrambles to win a slice in the booming obesity drug market.  The mov

3 Dirt-Cheap Stocks to Buy Right Now

08:30am, Monday, 22'nd Sep 2025
The major market indexes are bumping against all-time highs. It's not surprising, therefore, that many stocks are trading at steep valuations.
Metsera's shareholders could see significant bonuses if certain milestones are reached.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE